| Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. | |
| | |
MedLine Citation:
|
PMID: 16563599 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Prospective and retrospective studies have shown that empiric use of fibrinolytic agents in sudden cardiac arrest is safe and may improve outcomes in sudden cardiac arrest. Use of fibrinolytic agents for this indication is increasing in response to these data. METHODS: A prospective multicenter observational trial was performed in three emergency departments (EDs) to determine the proportion of patients that respond to empiric fibrinolysis with tenecteplase (TNK) after failing to respond to Advanced Cardiac Life Support (ACLS) measures. Cardiac arrest patients unresponsive to ACLS, who were given TNK by their treating physician, were enrolled in an outcome registry. Return of spontaneous circulation (ROSC), survival, complications, and neurological outcomes were recorded. RESULTS: Fifty patients received TNK after a mean of 30min of cardiac arrest and eight doses of ACLS medications. One hundred and thirteen concurrent control patients received standard ACLS measures. ROSC occurred in 26% of TNK patients (95% confidence interval (CI) 16-40%) compared to 12.4% (95% CI 6.9-20%) among ACLS controls (p=.04); 12% (4.5-24%) of TNK patients survived to admission compared to none in the control group (p=.0007); 4% (0.5-14%) survived to 24h (p=NS); and 4% (0.5-14%) survived to hospital discharge (p=NS). All survivors had a good neurological outcome (Cerebral Performance Category (CPC) 1-2). One intracranial hemorrhage (ICH) occurred. No other significant bleeding complications were observed. CONCLUSIONS: Empiric fibrinolysis with TNK in cardiac arrest is associated with increased ROSC and short term survival, and with survival to hospital discharge with good neurological function in patients who fail to respond to ACLS. Results may improve with earlier administration. Prospective controlled interventional trials are indicated to evaluate this promising new therapy. |
| | |
Authors:
|
William P Bozeman; Douglas M Kleiner; Kevin L Ferguson |
Related Documents
:
|
14975039 - Time-dependent interventions. 2750649 - Young adult survivors of sudden cardiac arrest: analysis of invasive evaluation of 22 s... 16735809 - Complications in paediatric anaesthesia. 8752819 - Myocardial dysfunction after resuscitation from cardiac arrest: an example of global my... 17962509 - Keeping cool: a case for hypothermia after cardiopulmonary resuscitation. 10861359 - Cardiac looping in the chick embryo: a morphological review with special reference to t... 18544389 - Association of device surface and biomaterials with immunologic sensitization after mec... 21059429 - Usefulness of serial assessment of b-type natriuretic peptide, troponin i, and c-reacti... 19812809 - Effects of levosimendan versus dobutamine on left atrial function in decompensated hear... |
Publication Detail:
|
Type: Comparative Study; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2006-03-23 |
Journal Detail:
|
Title: Resuscitation Volume: 69 ISSN: 0300-9572 ISO Abbreviation: Resuscitation Publication Date: 2006 Jun |
Date Detail:
|
Created Date: 2006-06-05 Completed Date: 2006-11-09 Revised Date: 2009-08-25 |
Medline Journal Info:
|
Nlm Unique ID: 0332173 Medline TA: Resuscitation Country: Ireland |
Other Details:
|
Languages: eng Pagination: 399-406 Citation Subset: IM |
Affiliation:
|
Department of Emergency Medicine, Wake Forest University, Medical Center Blvd., Winston-Salem, NC 27157, USA. wbozeman@wfubmc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Advanced Cardiac Life Support
/
methods* Blood Circulation* Emergency Medical Services Female Fibrinolytic Agents / therapeutic use* Heart Arrest / drug therapy*, mortality, therapy Humans Length of Stay Male Middle Aged Outcome Assessment (Health Care) Prospective Studies Survival Analysis Tissue Plasminogen Activator / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/tenecteplase; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biophysics of cardiopulmonary resuscitation with periodic z-axis acceleration or abdominal compressi...
Next Document: A public access defibrillation programme in non-inpatient hospital areas.